UCB Farchim

UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, with a primary focus on neurology and immunology. The company is dedicated to discovering and developing innovative medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB's portfolio includes established blockbusters like Cimzia for inflammatory diseases and Keppra and Vimpat for epilepsy, alongside a growing pipeline of next-generation therapies such as Bimzelx. UCB Farchim, based in Bulle, Switzerland, is a key strategic site for the company, housing advanced manufacturing facilities for both chemical and biological products. The company has recently expanded its reach into rare diseases and gene therapy through the strategic acquisitions of Ra Pharmaceuticals and Zogenix.